Global CRISPR Gene Detection and Diagnostics Market - Industry Trends and Forecast to 2029

Segmentation

Short Description
Global CRISPR Gene Detection and Diagnostic Market, By Class (Class 1- Multiple Effector Proteins and Class 2 -Single CrRNA-Binding Protein), Products & Services (Products and Services), Application (Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications and Others), Workflow (Sample Preparation, Pre-Amplification, CrRNA, Cas Enzymes and Sensing), End User (Hospitals, Diagnostic Centers, Biotechnology Companies, Academic and Research Institutes and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America) Industry Trends and Forecast to 2029

Market Definition:

CRISPR is clustered regularly interspaced short palindromic repeats, is a tool for genome editing, meaning it allows researchers to easily alter DNA sequences and modify gene function. It has many potential applications, including correcting genetic defects, treating and preventing the spread of diseases. CRISPR-based diagnostics have been used for a wide range of biomedical applications, such as the sensing of nucleic-acid-based biomarkers of infectious and non-infectious diseases and for detection of genetic diseases. The assay kits in CRISPR is made up of two components: a protein called Cas9 and a guide RNA, a string of nucleic acid molecules with a certain genetic code.
This CRISPR-Cas9 system has been modified for use in mammalian cells. By introducing a guide sequence (sgRNA) specific for our gene of interest, we can either knock-out specific genes through introducing frame shift mutations via Non-Homologous End Joining (NHEJ), or generate knock-in mutations.
CRISPR-Cas 9 system have extended the scope of diagnostics and services for use in gene and cell therapies. Pharmaceutical companies are investing heavily in R&D to develop new products, with a surge of gene and cell therapy agents now entering early development. The market players are investing would allow to achieve the goal of producing safe and effective treatments for patients who are in serious need.
Market Segmentation:
The global CRISPR gene detection and diagnostic market is categorized into six segments: class, products and services, application, workflow, end user, and distribution channel.
On the basis of class, the global CRISPR gene detection and diagnostic market is segmented into class 1- multiple effector proteins and class 2 -single crRNA-binding protein.
On the basis of products and services, the global CRISPR gene detection and diagnostic market is segmented into products and services.
On the basis of application, the global CRISPR gene detection and diagnostic market is segmented into biomedical diagnostics, genome engineering, drug discovery, agricultural applications and others.
On the basis of workflow, the global CRISPR gene detection and diagnostic market is segmented into sample preparation, pre-amplification, crRNA, Cas enzymes and sensing.
On the basis of end user, the global CRISPR gene detection and diagnostic market is segmented into hospitals, diagnostic centers, biotechnology companies, academic and research institutes and others.
On the basis of distribution channel, the global CRISPR gene detection and diagnostic market is segmented into direct tenders, retail sales.
Market Players

Some of the major players operating in the market are:

GenScript
Takara Bio Inc.
OriGene Technologies, Inc.
Horizon Discovery Ltd
Applied StemCell
GeneCopoeia, Inc.
ToolGen, Inc.
Agilent Technologies, Inc.
Synthego, BioVision Inc.
Hera Biolabs
Cellecta, Inc.
New England Biolabs
10x Genomics
ADDGENE
CasTag Biosciences
Merck KGaA
Integrated DNA Technologies, Inc. (A subsidiary of Danaher)
Thermo Fisher Scientific Inc.
 

Methodology